Cellectar Biosciences (CLRB) Set to Release Quarterly Earnings on Tuesday

Cellectar Biosciences (NASDAQ:CLRB) is expected to be announcing its Q3 2026 results before the market opens on Tuesday, November 10th. Analysts expect the company to post earnings of ($0.5565) per share and revenue of $17.00 million for the quarter. Individuals may review the information on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 8:30 AM ET.

Cellectar Biosciences (NASDAQ:CLRB) last released its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.52) by ($0.05). On average, analysts expect Cellectar Biosciences to post ($2.39) EPS for the current fiscal year and ($2.08) EPS for the next fiscal year.

Cellectar Biosciences Price Performance

CLRB traded up $0.02 during trading hours on Wednesday, reaching $1.33. The company’s stock had a trading volume of 40,562 shares, compared to its average volume of 363,719. The stock has a market cap of $12.57 million, a PE ratio of -0.35 and a beta of 0.65. Cellectar Biosciences has a fifty-two week low of $1.12 and a fifty-two week high of $4.70. The business’s 50-day moving average is $1.83 and its 200-day moving average is $2.62.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on CLRB shares. Brookline Capital Markets upgraded Cellectar Biosciences to a “strong-buy” rating in a research report on Sunday, July 12th. Wall Street Zen lowered Cellectar Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Cellectar Biosciences in a report on Thursday, October 15th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.00.

About Cellectar Biosciences

Cellectar Biosciences, Inc (NASDAQ: CLRB) is a clinical-stage biopharmaceutical company focused on developing targeted radiotherapeutics and oncology treatments. Its technology platform uses phospholipid ether compounds, which are designed to preferentially accumulate in cancer cells and other diseased tissues while limiting exposure to healthy tissue.

The company’s leading product candidate is iopofosine I 131, also known as CLR 131, a small-molecule radiopharmaceutical being studied for the treatment of hematologic malignancies, including relapsed or refractory multiple myeloma and certain types of lymphoma.